Research and Markets: Drug Developers Should Continue Integrating Well-Defined Genomics Assets into Supply Chains and Continue Efforts to Maximize Successful Target Validation.DUBLIN, Ireland -- Research and Markets has announced the addition of Optimizing Genomics Asset Management for High ROI (Return On Investment) The monetary benefits derived from having spent money on developing or revising a system. In the IT world, there are more ways to compute ROI than Carter has liver pills (and for those of you who never heard of that expression, it means a lot). - Evaluating Strategies to Support the Bio/Pharma Value Chain to their offering. The early wave of the genomics revolution witnessed a spectacular stock value decline. This was caused by the lack of transparency between the industrys innovating, investing and licensing arms, and by a high degree of speculation related to unrealistic market generation targets and lack of understanding of the technological complexities. The need to overcome the pharma industry's pipeline productivity crisis is forcing the genomics innovators innovators people who will try new things. early innovators important figures in the farming or client community because they are the leaders in the introduction of new techniques and management systems. and their partners to reshape their portfolio management. New asset allocation Asset Allocation The process of dividing a portfolio among major asset categories such as bonds, stocks or cash. The purpose of asset allocation is to reduce risk by diversifying the portfolio. strategies and valuation methodologies are needed to support the evolution to a new business model emphasizing investment in technological diversification Diversification A risk management technique that mixes a wide variety of investments within a portfolio. It is designed to minimize the impact of any one security on overall portfolio performance. Notes: Diversification is possibly the greatest way to reduce the risk. . The new wave of innovation is focusing on gene functionalities, population genomics, chemo- and pharmacogenomics Pharmacogenomics is the branch of pharmacology which deals with the influence of genetic variation on drug response in patients by correlating gene expression or single-nucleotide polymorphisms with a drug's efficacy or toxicity. . Drug developers should continue integrating well-defined genomics assets into their supply chains, work to maximize successful target validation See validate. validation - The stage in the software life-cycle at the end of the development process where software is evaluated to ensure that it complies with the requirements. and optimize optimize - optimisation alliance networks to ensure asset co-evolution and diversification. This report considers the evolution of the genomics sector, through an evaluation of the trends extracted from the key licensing, drug development and M&A deals. The challenges lying ahead for both innovators and their partners are revealed. Vital steps to integrate newly diversified diversified (di·verˑ·s genomics assets into the bio/pharma value chain are introduced followed by a novel way to assess the value of genomics innovation. The new asset valuation platform is based on blending quantitative real option methodologies and qualitative multidimensional mul·ti·di·men·sion·al adj. Of, relating to, or having several dimensions. mul  ti·di·men asset analyses. This report provides: --Insight into the dynamics of the genomics sector, as it diversifies to meet the challenge of the evolving bio/pharma supply chain --Survival strategies for potential postgenomics drug developers and successful exit strategies for failed genomics businesses --Novel portfolio management and option based asset valuation to support postgenomics drug developers, genomics licensees and innovators Contents include: THE EVOLUTION OF GENOMICS BUSINESS STRATEGIES A rising pipeline productivity crisis Transforming the 20th Century's medicine to 21st Century Biomedicine biomedicine /bio·med·i·cine/ (bi?o-med´i-sin) clinical medicine based on the principles of the natural sciences (biology, biochemistry, etc.).biomed´ical bi·o·med·i·cine n. 1. The evolution of the genomics-oriented sector The genomics value matrix: evolving towards prosperity Two evolution waves: from speculation to depression, realization and diversification The early wave: from speculation to realization Key factors that formed the early evolution wave The early wave of alliance strategies MLNM case study: Genomics assets used to boost integration Bayer case study: Genomics assets not enough to boost growth The early wave of M&A strategies Merck case study: the acquisition of Rosetta The new wave of genomics: investing in diversification Supporting supply chain integration with diversification Adding value through vertical integration - assessing recent deal value Accessing the best opportunities: key recommendations for success in accessing genomics Survival strategies for the horizontal genomics innovators Exit strategies for failed horizontal genomics innovators THE EVOLUTION OF GENOMICS PORTFOLIO VALUATION A novel view on the genomics business valuation landscape What forces the need for exploring new asset valuation methods? Evolving new genomics asset valuation methodologies Revealing the role of complexity in genomics business valuation Introducing a novel structural model to unfold unfold - inline genomics asset complexity Adding more depth to the proposed structural model Evolving the comlex dynamic asset structures Evolving hybrid models: real options plus structural equation For more information visit http://www.researchandmarkets.com/reports/c9519 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion